Bristol-Myers Squibb Co. (NYSE:BMY) and MedImmune LLC/AstraZeneca plc (LSE:AZN; NYSE:AZN) each have four disclosed products targeting distinct checkpoint modulators in their oncology pipelines. All products are mAbs specific for proteins occurring on T cells or antigen-presenting cells. MedImmune is drawing even with BMS by adding